187 related articles for article (PubMed ID: 28493609)
1. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
Mazonakis M; Lyraraki E; Damilakis J
Med Phys; 2017 Jul; 44(7):3866-3874. PubMed ID: 28493609
[TBL] [Abstract][Full Text] [Related]
2. Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease.
Kourinou KM; Mazonakis M; Lyraraki E; Papadaki HΑ; Damilakis J
Phys Med; 2019 Jan; 57():100-106. PubMed ID: 30738513
[TBL] [Abstract][Full Text] [Related]
3. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
[TBL] [Abstract][Full Text] [Related]
4. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk.
Filippi AR; Ragona R; Piva C; Scafa D; Fiandra C; Fusella M; Giglioli FR; Lohr F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):161-8. PubMed ID: 25863763
[TBL] [Abstract][Full Text] [Related]
5. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
[TBL] [Abstract][Full Text] [Related]
6. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma.
Hodgson DC; Koh ES; Tran TH; Heydarian M; Tsang R; Pintilie M; Xu T; Huang L; Sachs RK; Brenner DJ
Cancer; 2007 Dec; 110(11):2576-86. PubMed ID: 17941006
[TBL] [Abstract][Full Text] [Related]
7. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?
Aznar MC; Maraldo MV; Schut DA; Lundemann M; Brodin NP; Vogelius IR; Berthelsen AK; Specht L; Petersen PM
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):169-74. PubMed ID: 25754634
[TBL] [Abstract][Full Text] [Related]
8. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.
Koh ES; Tran TH; Heydarian M; Sachs RK; Tsang RW; Brenner DJ; Pintilie M; Xu T; Chung J; Paul N; Hodgson DC
Radiat Oncol; 2007 Mar; 2():13. PubMed ID: 17362522
[TBL] [Abstract][Full Text] [Related]
9. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
Maraldo MV; Jørgensen M; Brodin NP; Aznar MC; Vogelius IR; Petersen PM; Berthelsen AK; Christensen CB; Hjalgrim LL; Specht L
Pediatr Blood Cancer; 2014 Apr; 61(4):717-22. PubMed ID: 24660228
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for stage I seminoma of the testis: Organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model.
Mazonakis M; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2015 Nov; 42(11):6309-16. PubMed ID: 26520723
[TBL] [Abstract][Full Text] [Related]
11. Risk of developing radiogenic cancer following photon-beam radiotherapy for Graves' orbitopathy.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2018 Oct; 45(10):4775-4782. PubMed ID: 30105825
[TBL] [Abstract][Full Text] [Related]
12. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
13. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Ann Oncol; 2013 Aug; 24(8):2113-8. PubMed ID: 23619032
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
15. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group.
Maraldo MV; Dabaja BS; Filippi AR; Illidge T; Tsang R; Ricardi U; Petersen PM; Schut DA; Garcia J; Headley J; Parent A; Guibord B; Ragona R; Specht L
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):144-52. PubMed ID: 25670544
[TBL] [Abstract][Full Text] [Related]
16. The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era.
Hoppe BS; Bates JE; Mendenhall NP; Morris CG; Louis D; Ho MW; Hoppe RT; Shaikh M; Li Z; Flampouri S
Pract Radiat Oncol; 2020; 10(3):e147-e154. PubMed ID: 31586483
[TBL] [Abstract][Full Text] [Related]
17. Individualized 3D reconstruction of normal tissue dose for patients with long-term follow-up: a step toward understanding dose risk for late toxicity.
Ng A; Brock KK; Sharpe MB; Moseley JL; Craig T; Hodgson DC
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e557-63. PubMed ID: 22929861
[TBL] [Abstract][Full Text] [Related]
18. SECOND CANCER RISK FROM RADIATION THERAPY FOR COMMON SOLID TUMORS DIAGNOSED IN REPRODUCTIVE-AGED FEMALES.
Mazonakis M; Kachris S; Damilakis J
Radiat Prot Dosimetry; 2018 Dec; 182(2):208-214. PubMed ID: 29608744
[TBL] [Abstract][Full Text] [Related]
19. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
[TBL] [Abstract][Full Text] [Related]
20. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study.
Rechner LA; Modiri A; Stick LB; Maraldo MV; Aznar MC; Rice SR; Sawant A; Bentzen SM; Vogelius IR; Specht L
Acta Oncol; 2020 Aug; 59(8):879-887. PubMed ID: 32216586
[No Abstract] [Full Text] [Related]
[Next] [New Search]